(Q33403790)

English

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yong Sang Hong

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Young Suk Park

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ho Yeong Lim

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeeyun Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tae Won Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kyu-pyo Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sun Young Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ji Yeon Baek

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jee Hyun Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Keun-Wook Lee

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ik-Joo Chung

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sang-Hee Cho

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kyung Hee Lee

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sang Joon Shin

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hye Jin Kang

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dong Bok Shin

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sook Jung Jo

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jae Won Lee

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

10 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1125-1132

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the Korean version of the EORTC QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine as adjuvant treatment for stage III colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Contrast-enhanced computed tomography for the diagnosis of fatty liver: prospective study with same-day biopsy used as the reference standard

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970363-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70363-7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33403790&oldid=1570028459"